PRAXIS PRECISION MEDICINES INC (PRAX) competitors & alternatives
Health Care · NASDAQ
PRAXIS PRECISION MEDICINES INC (PRAX)'s top competitors and alternatives — its most similar public companies — include Biogen (BIIB), Ionis Pharmaceuticals (IONS), SUPERNUS PHARMACEUTICALS INC (SUPN), OVID THERAPEUTICS INC (OVID), ANAVEX LIFE SCIENCES CORP (AVXL), CAMP4 THERAPEUTICS CORP (CAMP), PTC THERAPEUTICS INC (PTCT), RHYTHM PHARMACEUTICALS INC (RYTM), Sarepta Therapeutics (SRPT), TAYSHA GENE THERAPIES INC (TSHA), DYNE THERAPEUTICS INC (DYN) and NEUMORA THERAPEUTICS INC (NMRA). These are PRAXIS PRECISION MEDICINES INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top PRAX competitors & alternatives
-
BiogenBIIBHealth Care
Biogen is a global biotechnology company developing and commercializing therapies across neurology, immunology, and rare genetic disease.
$197.74 (as of 2026-07-22) · market cap $29.8B
-
Ionis PharmaceuticalsIONSHealth Care
Pioneer in RNA-targeted antisense medicines with seven commercialized products and expanding late-stage pipeline across rare neurological and cardiometabolic…
$54.01 (as of 2026-07-22) · market cap $8.8B
-
SUPERNUS PHARMACEUTICALS INCSUPNHealth Care
Supernus is a biopharmaceutical company commercializing approved CNS treatments across ADHD, Parkinson's disease, postpartum depression, epilepsy, and migraine…
$46.94 (as of 2026-07-22) · market cap $2.8B
-
OVID THERAPEUTICS INCOVIDHealth Care
A biopharmaceutical company developing small molecule medicines targeting neuronal hyperexcitability to treat drug-resistant epilepsies, developmental…
$2.38 (as of 2026-07-22) · market cap $438M
-
ANAVEX LIFE SCIENCES CORPAVXLHealth Care
Anavex is a clinical-stage biotech developing sigma-1 receptor agonists for neurodegenerative and rare CNS disorders, with lead program ANAVEX 2-73 in multiple…
$2.55 (as of 2026-07-22) · market cap $234M
-
CAMP4 THERAPEUTICS CORPCAMPHealth Care
CAMP4 is pioneering a novel RNA-targeting platform to upregulate deficient genes in rare genetic diseases, starting with SYNGAP1-related developmental epilepsy.
$3.11 (as of 2026-07-22) · market cap $166M
-
PTC THERAPEUTICS INCPTCTHealth Care
PTC Therapeutics develops precision medicines and gene therapies targeting rare genetic disorders and serious diseases, generating revenue from approved…
$78.40 (as of 2026-07-22) · market cap $6.5B
-
RHYTHM PHARMACEUTICALS INCRYTMHealth Care
Rhythm Pharmaceuticals is a precision medicine company developing targeted MC4R agonist therapies for patients living with rare, severe obesity-related…
$103.97 (as of 2026-07-22) · market cap $7.1B
-
Sarepta TherapeuticsSRPTHealth Care
A biopharmaceutical leader in genetic medicine, specializing in innovative RNA-targeted therapies and gene treatments for Duchenne muscular dystrophy and rare…
$15.82 (as of 2026-07-22) · market cap $1.7B
-
TAYSHA GENE THERAPIES INCTSHAHealth Care
Taysha Gene Therapies is a clinical-stage biotech company pioneering AAV-based gene therapies to treat severe, rare monogenic diseases of the central nervous…
$5.66 (as of 2026-07-22) · market cap $1.8B
-
DYNE THERAPEUTICS INCDYNHealth Care
Dyne Therapeutics is a clinical-stage biotechnology company leveraging its proprietary FORCE platform to develop targeted therapies for serious,…
$23.21 (as of 2026-07-22) · market cap $3.8B
-
NEUMORA THERAPEUTICS INCNMRAHealth Care
Neumora Therapeutics is a clinical-stage biotechnology company developing precision medicine therapies for psychiatric and neurodegenerative brain disorders.
$1.54 (as of 2026-07-22) · market cap $298M
Not quite? Describe exactly what you want →
Peers are PRAXIS PRECISION MEDICINES INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: PRAXIS PRECISION MEDICINES INC (PRAX).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.